TEL
+ 86-21-6420 0566
English Synonyms 1,4-Bis((1,4,8,11-tetraazacyclotetradecan-1-yl)methyl)benzene
Код каталога 99759
CAS NO.110078-46-1
Чистота 98%
Номер MDLMFCD05662218
EINEC Molecular FormulaC28H54N8
Molecular Weight 502.782,
| категорию | Контент |
|---|---|
| Родовое имя | Плериксафор |
| Бренд: | Мозобил |
| Класс наркотиков | Hematopoietic Stem Cell Mobilizer, CXCR4 Antagonist |
| Механизм действия | Plerixafor is a selective CXCR4 antagonist that blocks the binding of stromal cell-derived factor-1α (SDF-1α) to CXCR4. This interaction helps mobilize hematopoietic stem cells (HSCs) from the bone marrow into the bloodstream. |
| Показания к применению | – Used in combination with granulocyte colony-stimulating factor (G-CSF) to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with non-Hodgkin’s lymphoma or multiple myeloma.<br>- Investigated for other uses, including wound healing and cancer treatment. |
| Лекарственные формы | Subcutaneous injection (20 mg/mL solution) |
| Администрация | Administered subcutaneously. A healthcare provider will give the injection and monitor the patient for at least 30 minutes to ensure no allergic reaction occurs. |
| Фармакокинетика | – Peak plasma concentrations occur within 30 to 60 minutes after subcutaneous injection.<br>- Elimination is primarily renal, with approximately 70% of the dose excreted unchanged in urine within the first 24 hours.<br>- Terminal half-life is between 3 and 5 hours. |
| Побочные эффекты | – Common: Injection site irritation, nausea, vomiting, diarrhea, headache, dizziness, tiredness, joint pain.<br>- Serious: Allergic reactions (including anaphylactic shock), splenomegaly, splenic rupture. |
| Меры предосторожности | – Not recommended for patients with leukemia.<br>- Use with caution in patients with renal impairment; dose adjustment is required for those with moderate to severe renal impairment.<br>- Pregnancy Category D: May cause fetal harm; effective contraception is advised.<br>- Not recommended for breastfeeding. |
| Память | Store at room temperature (15°C to 30°C); protect from light and moisture. |
| Застройщик | Genzyme Corporation (a Sanofi company) |
| Дата утверждения | Approved by the FDA in December 2008 |
Отказ от ответственности: приведенный выше контент предназначен только для справки и общения среди инсайдеров отрасли и не гарантирует его точность или полноту. Согласно соответствующим законам и правилам, а также правилам этого веб-сайта, подразделения или лица, которые покупают соответствующие товары, должны получить действительные квалификации и условия квалификации.
Фабрика и отгрузка
